Lucis Secures $20 Million Series A to Scale AI-Powered Preventive Health Platform Across Europe
核心洞察
Lucis (搜索) raised $20 million in Series A funding led by Singular (搜索), bringing total funding to $28 million just four months after an $8 million seed round.
The AI-powered platform analyzes over 110 blood biomarkers (搜索) and has demonstrated that 75% of users improved at least three biomarkers without medication after six months.
The company plans to expand into Spain, Germany, and Italy by 2026, targeting Europe's preventive healthcare market where 1.8 million deaths annually could be prevented through early intervention.
Paris-based Lucis (搜索) has secured $20 million in Series A funding led by Singular (搜索), with participation from General Catalyst (搜索), Y Combinator (搜索), and angel investors including Céline Lazorthes and Manu Lecomte. The funding will support the company's expansion of its AI-powered preventive health platform across Europe and further development of its health companion application.
The new financing comes just four months after Lucis (搜索) raised an $8 million seed round in December 2025, bringing the company's total funding to approximately $28 million. The rapid fundraising reflects growing demand for proactive and data-driven healthcare solutions in the European market.
Platform Technology and Clinical Outcomes
Founded in 2025 by Maxime Berthelot, Baptiste Debever, and Max Guérois, Lucis (搜索) offers a preventive healthcare platform that analyzes more than 110 blood biomarkers (搜索) spanning metabolic health (搜索), hormones (搜索), cardiovascular risk (搜索), inflammation (搜索), and nutrient levels (搜索). The company combines biomarker testing, longitudinal health tracking, and AI-powered analysis to deliver personalized recommendations around nutrition, supplementation, lifestyle changes, and follow-up testing.
The platform's recommendations are continuously refined using updated health data and are reviewed by physicians to help users understand what actions to take based on their biomarker results. Lucis (搜索) has established partnerships with laboratory groups including Eurofins (搜索) and Randox (搜索) to conduct the testing.
Early user data indicates significant clinical impact. Among users who completed six-month follow-up testing, 75% improved at least three biomarkers (搜索) without medication. The company also reports that more than 80% of users chose to retest, reflecting ongoing engagement with personal health monitoring. Notably, 99.9% of users initially tested had at least one biomarker outside optimal ranges, often without prior awareness.
Market Expansion and User Growth
Lucis (搜索) currently serves more than 10,000 users across France, the UK, Ireland, and Portugal, and has processed more than one million biomarker tests. The company employs a team of 20 across engineering, clinical operations, growth, and operations, while also working with a medical board and a network of physicians providing clinical oversight.
The company plans to expand into Spain, Germany, and Italy by the end of 2026 while continuing to invest in personalization, longitudinal monitoring, and clinical safety features.
Addressing European Healthcare Challenges
The World Health Organisation's June 2025 European report attributes 1.8 million avoidable deaths annually across the WHO European Region to non-communicable diseases (搜索), at an economic cost of $514 billion. The agency argues that 60% of those deaths could be prevented through risk-factor reduction, representing the market gap Lucis (搜索) aims to address.
"We've seen the devastating impact of late-stage diagnosis first-hand. The science is already there; what's missing is a system designed to act before symptoms appear," said Maxime Berthelot, Co-founder and CEO of Lucis (搜索). "By combining biomarker data and AI-driven clinical insights, we can catch what the system misses. Europe deserves a healthcare model that doesn't wait for people to get sick. We are making prevention the default, rather than a privilege."
Jeremy Uzan, co-founder and general partner at Singular (搜索), commented: "Europe's preventive health category will be won by platforms that unite clinical credibility with AI at scale. Lucis (搜索) has moved with remarkable velocity, reaching 10,000 users in under a year, delivering measurable outcomes and building a compounding data advantage that sets the standard for the category."
The company believes Europe's healthcare system remains heavily reactive despite increased awareness around preventive care and chronic disease prevention, positioning itself to create a healthcare model focused on early detection, continuous monitoring, and personalized interventions before symptoms appear.